CASPORYN HC

Manufacturer
Casper Pharma LLC | Eugia Pharma Specialities Limited
Effective date
2024-06-03
Label type
Human Prescription Drug Label
Version
6
Source
legacy-cache
Hydrated at
2026-08-01 21:01:08

Label at a glance#

ProductCASPORYN HC
Active ingredientHYDROCORTISONE, NEOMYCIN SULFATE, POLYMYXIN B SULFATE
Label structure10 sections

Dosage and administration

Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator. For adults, 4 drops of the suspension should be instilled into the affected ear 3 or 4 times daily. For children, 3 drops are suggested because of the smaller capacity of the ear canal. The patient should lie with the affected ear upward and then ...

Label contents#

Full prescribing information#

DESCRIPTION

DESCRIPTION SECTION

CASPORYN HC (neomycin and polymyxin B sulfates and hydrocortisone otic suspension, USP) is a sterile antibacterial and anti-inflammatory suspension for otic use. Each mL contains: neomycin sulfate equivalent to 3.5 mg neomycin base, polymyxin B sulfate equivalent to 10,000 polymyxin B units, and hydrocortisone 10 mg (1%). The vehicle contains thimerosal 0.01% (added as a preservative) and the inactive ingredients cetyl alcohol, propylene glycol, polysorbate 80, and Water for Injection. Sulfuric acid may be added to adjust pH.

Neomycin sulfate is the sulfate salt of neomycin B and C, which are produced by the growth of Streptomyces fradiae Waksman (Fam. Streptomycetaceae). It has a potency equivalent of not less than 600 mcg of neomycin standard per mg, calculated on an anhydrous basis. The structural formulae are:

casporyn-hc-neomycin-struc1casporyn-hc-neomycin-struc1

Polymyxin B sulfate is the sulfate salt of polymyxin B1 and B2, which are produced by the growth of Bacillus polymyxa (Prazmowski) Migula (Fam. Bacillaceae). It has a potency of not less than 6,000 polymyxin B units per mg, calculated on an anhydrous basis. The structural formulae are:

casporyn-hc-polymyxin-struc1casporyn-hc-polymyxin-struc1


Hydrocortisone, 11β, 17, 21-trihydroxypregn-4-ene-3, 20-dione, is an anti-inflammatory hormone. Its structural formula is:

casporyn-hc-hydrocortisone-struc1casporyn-hc-hydrocortisone-struc1

CLINICAL PHARMACOLOGY

CLINICAL PHARMACOLOGY SECTION

Corticoids suppress the inflammatory response to a variety of agents and they may delay healing. Since corticoids may inhibit the body's defense mechanism against infection, a concomitant antimicrobial drug may be used when this inhibition is considered to be clinically significant in a particular case.

The anti-infective components in the combination are included to provide action against specific organisms susceptible to them. Neomycin sulfate and polymyxin B sulfate together are considered active against the following microorganisms: Staphylococcus aureus, Escherichia coli, Haemophilus influenzae, Klebsiella-Enterobacter species, Neisseria species and Pseudomonas aeruginosa. This product does not provide adequate coverage against Serratia marcescens and streptococci, including Streptococcus pneumoniae.

The relative potency of corticosteroids depends on the molecular structure, concentration, and release from the vehicle.

INDlCATlONS AND USAGE

INDICATIONS & USAGE SECTION

For the treatment of superficial bacterial infections of the external auditory canal caused by organisms susceptible to the action of the antibiotics, and for the treatment of infections of mastoidectomy and fenestration cavities caused by organisms susceptible to the antibiotics.

CONTRAINDICATIONS

CONTRAINDICATIONS SECTION

This product is contraindicated in those individuals who have shown hypersensitivity to any of its components, and in herpes simplex, vaccinia, and varicella infections.

WARNINGS

WARNINGS SECTION

Neomycin can induce permanent sensorineural hearing loss due to cochlear damage, mainly destruction of hair cells in the organ of Corti. The risk is greater with prolonged use. Therapy should be limited to 10 consecutive days (see PRECAUTIONS-General). Patients being treated with eardrops containing neomycin should be under close clinical observation. CASPORYN HC should not be used in any patient with a perforated tympanic membrane.

Discontinue promptly if sensitization or irritation occurs.

Neomycin sulfate may cause cutaneous sensitization. A precise incidence of hypersensitivity reactions (primarily skin rash) due to topical neomycin is not known.

When using neomycin-containing products to control secondary infection in the chronic dermatoses, such as chronic otitis externa or stasis dermatitis, it should be borne in mind that the skin in these conditions is more liable than is normal skin to become sensitized to many substances, including neomycin. The manifestation of sensitization to neomycin is usually a low-grade reddening with swelling, dry scaling, and itching; it may be manifest simply as a failure to heal. Periodic examination for such signs is advisable, and the patient should be told to discontinue the product if they are observed. These symptoms regress quickly on withdrawing the medication. Neomycin containing applications should be avoided for the patient thereafter.

PRECAUTIONS

SPL UNCLASSIFIED SECTION

General:

GENERAL PRECAUTIONS SECTION

As with other antibiotic preparations, prolonged use may result in overgrowth of nonsusceptible organisms, including fungi.

If the infection is not improved after 1 week, cultures and susceptibility tests should be repeated to verify the identity of the organism and to determine whether therapy should be changed.

Treatment should not be continued for longer than 10 days.

Allergic cross-reactions may occur which could prevent the use of any or all of the following antibiotics for the treatment of future infections: kanamycin, paromomycin, streptomycin, and possibly gentamicin.

Information for Patients:

INFORMATION FOR PATIENTS SECTION

Avoid contaminating the bottle tip with material from the ear, fingers, or other source. This caution is necessary if the sterility of the drops is to be preserved.

If sensitization or irritation occurs, discontinue use immediately and contact your physician.

SHAKE WELL BEFORE USING.

Carcinogenesis, Mutagenesis, Impairment of Fertility:

CARCINOGENESIS & MUTAGENESIS & IMPAIRMENT OF FERTILITY SECTION

Long-term studies in animals (rats, rabbits, mice) showed no evidence of carcinogenicity attributable to oral administration of corticosteroids.

Pregnancy

SPL UNCLASSIFIED SECTION

Teratogenic effects:

TERATOGENIC EFFECTS SECTION

Corticosteroids have been shown to be teratogenic in rabbits when applied topically at concentrations of 0.5% on days 6 to 18 of gestation and in mice when applied topically at a concentration of 15% on days 10 to 13 of gestation. There are no adequate and well-controlled studies in pregnant women. Corticosteroids should be used during pregnancy only if the potential benefit justifies the potential risk to the fetus.

Nursing Mothers:

NURSING MOTHERS SECTION

Hydrocortisone appears in human milk following oral administration of the drug. Since systemic absorption of hydrocortisone may occur when applied topically, caution should be exercised when CASPORYN HC is used by a nursing woman.

Pediatric Use:

PEDIATRIC USE SECTION

The safety and effectiveness of CASPORYN HC in otitis externa have been established in pediatric patients.

Geriatric Use:

GERIATRIC USE SECTION

Clinical studies of CASPORYN HC did not include sufficient numbers of subjects aged 65 and over to determine whether they respond differently from younger subjects. Other reported clinical experience has not identified differences in responses between the elderly and younger patients.

ADVERSE REACTIONS

ADVERSE REACTIONS SECTION

Neomycin occasionally causes skin sensitization. Ototoxicity and nephrotoxicity have also been reported (see WARNINGS). Adverse reactions have occurred with topical use of antibiotic combinations including neomycin and polymyxin B. Exact incidence figures are not available since no denominator of treated patients is available. The reaction occurring most often is allergic sensitization.

The following local adverse reactions have been reported with topical corticosteroids, especially under occlusive dressings: burning, itching, irritation, dryness, folliculitis, hypertrichosis, acneiform eruptions, hypopigmentation, perioral dermatitis, allergic contact dermatitis, maceration of the skin, secondary infection, skin atrophy, striae and miliaria. Stinging and burning have been reported rarely when this drug has gained access to the middle ear.

To report SUSPECTED ADVERSE REACTIONS, contact Casper Pharma LLC. at 1-844-5-CASPER (1-844-522-7737) or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

DOSAGE AND ADMINISTRATION

DOSAGE & ADMINISTRATION SECTION

Therapy with this product should be limited to 10 consecutive days. The external auditory canal should be thoroughly cleansed and dried with a sterile cotton applicator.

For adults, 4 drops of the suspension should be instilled into the affected ear 3 or 4 times daily.

For children, 3 drops are suggested because of the smaller capacity of the ear canal.

The patient should lie with the affected ear upward and then the drops should be instilled. This position should be maintained for 5 minutes to facilitate penetration of the drops into the ear canal. Repeat, if necessary, for the opposite ear.

If preferred, a cotton wick may be inserted into the canal and then the cotton may be saturated with the suspension. This wick should be kept moist by adding further suspension every 4 hours. The wick should be replaced at least once every 24 hours.

SHAKE WELL BEFORE USING.

HOW SUPPLIED

HOW SUPPLIED SECTION

10 mL bottle (NDC 70199-011-10). Store at 15° to 25°C (59° to 77°F).

Rx only

KEEP OUT OF REACH OF CHILDREN.

Manufactured for:

Casper Pharma LLC

East Brunswick, NJ 08816

Code No.: TS/DRUGS/13/2010

Made in India

PIB01110-03

Issued: 04/2019



PACKAGE LABEL.PRINCIPAL DISPLAY PANEL

CASPORYN HC
(neomycin and polymyxin B sulfates and hydrocortisone otic suspension, USP)
Sterile
FOR USE IN EARS.
10 mL

NDC 70199-011-10


casporyn-hc-carton-label
casporyn-hc-carton-label

DailyMed Dashboard NDC Coverage#

NDC, Dashboard title, SPL version table
NDCDashboard titleSPL versionValidationDashboard ZIP
70199-011CASPORYN HC (NEOMYCIN AND POLYMYXIN B SULFATES AND HYDROCORTISONE OTIC) SUSPENSION [CASPER PHARMA LLC]6Legacy NDC20240606_14bb3363-1b52-4596-afcc-47457b064217.zip

Products#

Every source-derived product name is available through these pages.

DailyMed product names page 1 of 1 · 13 matching rows.

NDC Codes#

Product NDC, Package NDC table
Product NDCPackage NDC
70199-01170199-011-10

Ingredients#

Every source-derived ingredient row is available through these pages.

DailyMed ingredient rows page 1 of 1 · 9 matching rows.

Source Document#

Source XML

Orange Book application contexts#

All distinct exact application/product contexts derived from this label’s complete NDC list are paginated below.

Orange Book application contexts page 1 of 1 · 1 matching rows.

Source provenance: Browse the complete Orange Book source catalog · source snapshot 45.

Orange Book products#

Current product rows page 1 of 1 · 1 matching rows.

Application-product, Trade name, Ingredient table
Application-productTrade nameIngredientStrengthDosage form / routeTE codesRLD / RSApproval date
N060613-001CASPORYN HCHYDROCORTISONE; NEOMYCIN SULFATE; POLYMYXIN B SULFATE1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, Approved before 1982

Therapeutic equivalence codes#

Current TE-code rows page 1 of 1 · 1 matching rows.

Application-product, TE code table
Application-productTE code
N060613-001AT

Observed Orange Book product history#

Observed FDA ZIP history: Each table is queried independently by exact application/product key from successfully parsed Orange Book snapshots. Capture times identify archived source observations; absence or a change between snapshots is not inferred. FDA publication files that were not recoverable as structured ZIP data are not represented as states.

Product history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTrade nameStrengthDosage form / routeProduct TE source textRLD / RSApproval dateSource SHA-256
2026-11-14 07:37:172026-10N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, Approved before 1982d4dbc9d85df4…
2026-10-15 13:18:302026-09N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, Approved before 1982c2088c7a36db…
2026-09-14 22:38:342026-08N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, Approved before 198284e616aacf4f…
2026-08-18 06:07:402026-07N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 198231067a03dcf5…
2025-08-23 18:47 UTC2025-08N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19826a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 198203ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19822680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19825bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 198279d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19821e350fbaab3a…
2024-05-31 18:47 UTC2024-05N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19828072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19825c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19825d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19824b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 198274a2ff9319b5…
2022-03-09 01:35 UTC2022-03N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 198287673890dc5c…
2021-03-12 10:30 UTC2021-03N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19825aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19828869cabd3fbd…
2020-11-12 02:37 UTC2020-11N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982c0c555d07b60…
2019-12-14 00:12 UTC2019-12N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19823f01610625f2…
2019-09-15 20:21 UTC2019-09N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982b00525d2431f…
2019-07-19 19:46 UTC2019-07N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19826a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19821c564ffb4f44…
2023-12-20 04:57 UTC2023-12N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19829b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19823f0d92c62455…
2023-05-13 08:27 UTC2023-05N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 1982053a50430f4f…
2023-01-26 05:58 UTC2023-01N060613-001CASPORYN HC1%;EQ 3.5MG BASE/ML;10,000 UNITS/MLSUSPENSION/DROPS / OTICATRLD, RS, Approved before 19823bdfa0b2c4d7…

Observed Orange Book normalized TE history#

Normalized TE history page 1 of 2 · 45 observed states.

Captured, Edition, Application-product table
CapturedEditionApplication-productTE codeOrderSource SHA-256
2026-11-14 07:37:172026-10N060613-001AT1d4dbc9d85df4…
2026-10-15 13:18:302026-09N060613-001AT1c2088c7a36db…
2026-09-14 22:38:342026-08N060613-001AT184e616aacf4f…
2026-08-18 06:07:402026-07N060613-001AT1caaa826d4ba7…
2026-02-19 14:30 UTC2026-02N060613-001AT1011fe1cb6892…
2025-12-14 10:44 UTC · 2 captures of this ZIP2025-12N060613-001AT131067a03dcf5…
2025-08-23 18:47 UTC2025-08N060613-001AT16a471c1ec25d…
2025-03-22 03:13 UTC · 3 captures of this ZIP2025-03N060613-001AT1fd3edfee7708…
2025-02-26 10:13 UTC · 3 captures of this ZIP2025-02N060613-001AT1b8a1b40f171c…
2025-01-19 17:59 UTC · 7 captures of this ZIP2025-01N060613-001AT103ed91905a0d…
2024-12-13 21:23 UTC · 2 captures of this ZIP2024-12N060613-001AT12680178bc6a6…
2024-09-14 05:58 UTC · 2 captures of this ZIP2024-09N060613-001AT15bbf6a4d5a75…
2024-11-08 22:44 UTC · 3 captures of this ZIP2024-11N060613-001AT1d8e5a09893c0…
2024-10-29 15:01 UTC2024-10N060613-001AT1d06236e962d9…
2024-08-13 05:28 UTC · 3 captures of this ZIP2024-08N060613-001AT179d66fd596c7…
2024-07-13 05:37 UTC · 2 captures of this ZIP2024-07N060613-001AT1301d65b070ca…
2024-06-18 03:08 UTC · 5 captures of this ZIP2024-06N060613-001AT11e350fbaab3a…
2024-05-31 18:47 UTC2024-05N060613-001AT18072bd15b7f6…
2022-06-29 02:47 UTC · 2 captures of this ZIP2022-06N060613-001AT15c6f7cd8ea54…
2022-04-08 23:34 UTC2022-04N060613-001AT15d02ea3f76ae…
2022-04-04 05:41 UTC2022-04N060613-001AT14b0b4de00fa7…
2019-12-13 00:20 UTC2019-12N060613-001AT174a2ff9319b5…
2022-03-09 01:35 UTC2022-03N060613-001AT1bb7c543d1eb4…
2021-12-28 21:50 UTC2021-12N060613-001AT1782e0a99824c…
2021-05-05 16:15 UTC · 3 captures of this ZIP2021-05N060613-001AT187673890dc5c…
2021-03-12 10:30 UTC2021-03N060613-001AT15aa47cf7b7d7…
2020-12-22 03:56 UTC2020-12N060613-001AT18869cabd3fbd…
2020-11-12 02:37 UTC2020-11N060613-001AT1c0c555d07b60…
2019-12-14 00:12 UTC2019-12N060613-001AT13f01610625f2…
2019-09-15 20:21 UTC2019-09N060613-001AT1b00525d2431f…
2019-07-19 19:46 UTC2019-07N060613-001AT1ea99ee380514…
2024-03-16 18:09 UTC · 4 captures of this ZIP2024-03N060613-001AT16a51e52b5d6a…
2024-02-18 07:12 UTC2024-02N060613-001AT11c564ffb4f44…
2023-12-20 04:57 UTC2023-12N060613-001AT1ea1830bbd6c7…
2023-11-28 05:40 UTC · 2 captures of this ZIP2023-11N060613-001AT1a72a2bbeb626…
2023-10-25 00:34 UTC · 2 captures of this ZIP2023-10N060613-001AT19b2671bbb829…
2023-07-15 15:27 UTC · 2 captures of this ZIP2023-07N060613-001AT1a67488948f0b…
2023-06-13 01:57 UTC · 3 captures of this ZIP2023-06N060613-001AT13f0d92c62455…
2023-05-13 08:27 UTC2023-05N060613-001AT1053a50430f4f…
2023-01-26 05:58 UTC2023-01N060613-001AT13bdfa0b2c4d7…

openFDA label cross-check#

OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.

Matched openFDA labels page 1 of 1 · 1 matching rows.

Brand, Generic, Manufacturer table
BrandGenericManufacturerSPL set IDEffective dateAvailable safety fieldsJoin
66329ed5-3be4-49c0-aa8e-1ece97ca392a14bb3363-1b52-4596-afcc-47457b0642172025-07-31Warnings, Adverse reactionsExact identifier
spl set id: 14bb3363-1b52-4596-afcc-47457b064217

Reported adverse events (FAERS/openFDA)#

Adverse event summaries are temporarily unavailable. Other product information remains available.